Innate Pharma SA Files Form 6-K
Ticker: IPHYF · Form: 6-K · Filed: May 24, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | May 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
Innate Pharma SA filed a standard 6-K, no major news.
AI Summary
On May 24, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and does not contain specific financial figures or significant business updates beyond the filing itself. The company is incorporated in France and its fiscal year ends on December 31st.
Why It Matters
This filing indicates routine reporting for a foreign private issuer, providing transparency to investors about their regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain material non-public information that would typically affect stock price.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- May 24, 2024 (date) — Filing Date
- 001-39084 (other) — Commission File Number
FAQ
What type of filing is this?
This is a Form 6-K report of a foreign private issuer.
Who is the registrant?
The registrant is Innate Pharma S.A.
When was this report filed?
The report was filed on May 24, 2024.
What is the company's principal executive office address?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA indicates it files annual reports under Form 20-F.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-05-24 06:35:36
Filing Documents
- a6k-iphx240524.htm (6-K) — 9KB
- exhibit991-240524.htm (EX-99.1) — 26KB
- 0001598599-24-000040.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date May 24, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer